<< Back to Press Releases Page
ADHD drug Strattera/Atomoxetine linked to increased thoughts of suicide in children
Parents have been warned by the MHRA (Medicines and Healthcare products Regulatory Agency) that the ADHD (Attention Deficit Hyperactivity Disorder) drug Strattera may increase thoughts of suicide in their children.
The warning comes following new studies, involving over 1000 patients, which identified an increased risk of suicidal thoughts and behaviour in children and teenagers treated with Strattera. Five cases of suicidal thoughts were seen among 1,357 young patients, compared with no cases among 851 patients taking placebos (sugar pills) during trials.
Strattera also known as Atomoxetine was licensed for use in July 2004 to treat ADHD and it is estimated that up to 15,000 patients have been treated with it since it was marketed.
The non-stimulant based drug was the first type of medication to be licensed in the UK for 30 years. It was heralded as an advance by many doctors because one dose lasts for 24 hours. Older methylphenidate based medicine such as Ritalin cause insomnia, so are not taken in the evening, meaning symptoms are not controlled at night or in the early morning.
The MHRA advises, “those who are concerned or unwell should consult their doctor to discuss the best course of action”.
If you believe you or your child have been adversely affected by this drug or would like further information then please contact Stephen Hanbury of our Product Liability Team.